Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New eczema drug shows promise in early trial

NCT ID NCT06723405

First seen Jan 04, 2026 · Last updated May 25, 2026 · Updated 18 times

Summary

This study tested an experimental drug, EVO301, in 71 adults with moderate-to-severe atopic dermatitis (eczema). The goal was to see if the drug safely reduces skin redness, thickness, and itch. Participants received either EVO301 or a placebo, and doctors measured changes in skin severity over time.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (AD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Clinical Trials New Zealand Ltd

    Hamilton, 3204, New Zealand

  • Cornerstone Dermatology

    Coorparoo, QLD 4151, Australia

  • Momentum Clinical Research Darlinghurst

    Darlinghurst, NSW 2010, Australia

  • Momentum Clinical Research Dunedin

    Dunedin, 9016, New Zealand

  • Momentum Clinical Research Kapiti

    Paraparaumu, 5032, New Zealand

  • Momentum Clinical Research Lower Hutt

    Hutt Central, 5010, New Zealand

  • Momentum Clinical Research Pukekohe

    Pukekohe, 2120, New Zealand

  • Optimal Clinical Trials

    Auckland, 1010, New Zealand

  • Optimal Clinical Trials North

    Auckland, 0632, New Zealand

  • Pacific Clinical Research Network (PCRN) Auckland

    Auckland, 0622, New Zealand

  • Pacific Clinical Research Network (PCRN) Christchurch

    Christchurch, 8013, New Zealand

  • Pacific Clinical Research Network (PCRN) Tasman

    Nelson, 7011, New Zealand

Conditions

Explore the condition pages connected to this study.